Association Between Tumor Necrosis Factor-α Antagonists and Risk of Cancer in Patients With Inflammatory Bowel Disease

IMPORTANCE A Cochrane review and network meta-analysis concluded that there is need for more research on adverse effects, including cancer, after treatment with tumor necrosis factor a (TNF-alpha) antagonists and that national registries and large databases would provide relevant sources of data to evaluate these effects. OBJECTIVE To investigate whether patients with inflammatory bowel disease (IBD) exposed to TNF-alpha antagonists were at increased risk of developing cancer. DESIGN, SETTING, AND PARTICIPANTS Nationwide register-based cohort study in Denmark, 1999-2012. Participants were 56 146 patients 15 years or older with IBD identified in the National Patient Registry, of whom 4553 (8.1%) were exposed to TNF-alpha antagonists. Cancer cases were identified in the Danish Cancer Registry. MAIN OUTCOMES AND MEASURES Rate ratios (RRs) for incident cancer (overall and site-specific) comparing TNF-alpha antagonist users and nonusers, estimated using Poisson regression adjusted for age, calendar year, disease duration, propensity scores, and use of other IBD medications. RESULTS During 489 433 person-years of follow-up (median, 9.3 years [interquartile range, 4.2-14.0]), 81 of 4553 patients exposed to TNF-alpha antagonists (1.8%) (median follow-up, 3.7 years [interquartile range, 1.8-6.0]) and 3465 of 51 593 unexposed patients (6.7%) developed cancer, yielding a fully adjusted RR of 1.07 (95% CI, 0.85-1.36). There was no significantly increased risk of cancer by TNF-alpha antagonist exposure. No site-specific cancers were in significant excess in fully adjusted models. [GRAPHICS] CONCLUSIONS AND RELEVANCE In this Danish nationwide study, exposure to TNF-alpha antagonists among patients with IBD was not associated with an increased risk of cancer over a median follow-up of 3.7 years among those exposed. An increased risk associated with longer-term accumulated doses and follow-up cannot be excluded.